findmyKOL

Daron Street, MD

Basic profile

Oklahoma Cancer Specialists and Research Institute

ORCIDNone on fileNPI
RegionTulsa, OK · South CentralSpecialtyGynecologic OncologyFocusOncology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Daron Street is an Oncology physician affiliated with Oklahoma Cancer Specialists and Research Institute. OpenAlex indexes 16 publications with 474 citations (h-index 11).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
16publications

Distinct works indexed by OpenAlex.

474citations

Total citations across indexed works.

11h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    40.9%
    Platinum-based Drug16.2%
    Oxaliplatin98%Carboplatin2%
    Part B, office-administered18 patients
    PD-1 inhibitor14.7%
    Pembrolizumab100%
    Part B, office-administered17 patients

    + 3 more classes in this area

  • Blood & clotting

    35.1%
    Iron, parenteral preparations35.1%
    Ferric carboxymaltose100%
    Part B, office-administered21 patients
    Factor Xa inhibitor0%
    Eliquis100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    19%
    Serotonin-3 Receptor Antagonist10%
    Granisetron91%Palonosetron hcl7%Ondansetron hydrochloride2%Ondansetron Hcl0%
    Part D + Part B34 patients
    Substance P/Neurokinin-1 Receptor Antagonist9%
    Aprepitant100%
    Part B, office-administered24 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”